Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a virus challenge model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  McBride, Jacqueline M ^a   Lim, Jeremy J ^a   Burgess, Tracy ^a   Deng, Rong ^a   Derby, Michael A ^a,d   Maia, Mauricio ^a   Horn, Priscilla ^a   Siddiqui, Omer ^b   Sheinson, Daniel ^a   Chen Harris, Haiyin ^a   Newton, Elizabeth M ^a   Fillos, Dimitri ^a   Nazzal, Denise ^a   Rosenberger, Carrie M ^a   Ohlson, Maikke B ^a,e   Lambkin Williams, Rob ^c   Fathi, Hosnieh ^c   Harris, Jeffrey M ^a   Tavela, Jorge A ^a  

^a GENENTECH INC   (United States)

^b Allakos Inc   (United States)

^c Queen Mary BioEnterprises Innovation Centre   (United Kingdom)

^d Department of Microbiology ^*  (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Influenza A virus; MHAA4549A; Monoclonal antibodies

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; DRUG ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HUMAN MONOCLONAL ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MHAA 4549A; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; OSELTAMIVIR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; ID50 (INFECTIOUS); INFLUENZA A (H3N2); INFLUENZA A VIRUS (A/WISCONSIN/67/2005 (H3N2)); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; INTENTION TO TREAT ANALYSIS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SERUM; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM ASSESSMENT; TISSUE CULTURE; VACCINE IMMUNOGENICITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; INFLUENZA; NORMAL HUMAN; PATHOGENICITY; PHARYNX DISEASE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEALTHY VOLUNTEERS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; NASOPHARYNGEAL DISEASES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 85032467827     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01154-17     Document Type: Article

References (32)

1. World Health Organization. 2016. Influenza (seasonal) fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 17 August 2015.
2. Dao CN, Kamimoto L, Nowell M, Reingold A, Gershman K, Meek J, Arnold KE, Farley M, Ryan P, Lynfield R, Morin C, Baumbach J, Hancock E, Zansky S, Bennett NM, Thomas A, Vandermeer M, Kirschke DL, Schaffner W, Finelli L, Emerging Infections Program Network. 2010. Adult hospitalizations for laboratory-positive influenza during the 2005–2006 through 2007-2008 seasons in the United States. J Infect Dis 202:881– 888. https://doi.org/10.1086/655904.
3. Doshi S, Kamimoto L, Finelli L, Perez A, Reingold A, Gershman K, Yousey-Hindes K, Arnold K, Ryan P, Lynfield R, Morin C, Baumbach J, Hancock EB, Bennett NM, Zansky S, Thomas A, Schaffner W, Fry AM. 2011. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005–2009. J Infect Dis 204:1848 –1856. https://doi.org/10.1093/infdis/jir648.
4. Lee N, Ison MG. 2012. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 17:143–157. https://doi.org/10.3851/IMP2059.
5. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340. https://doi.org/10.1001/jama.292.11.1333.
6. Kandel R, Hartshorn KL. 2001. Prophylaxis and treatment of influenza virus infection. BioDrugs 15:303–323. https://doi.org/10.2165/00063030-200115050-00003.
7. Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 54: 4568 – 4574. https://doi.org/10.1128/AAC.00474-10.
8. Monto AS, Moult AB, Sharp SJ. 2000. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther 22:1294–1305. https://doi .org/10.1016/S0149-2918(00)83026-X.
9. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY. 1999. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 180:254 –261. https://doi.org/10.1086/314904.
10. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuramini-dase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845–1850.
11. Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, Fong R, Yan D, Kim J, Zhang J, Lee WP, Estevez A, Coons M, Xu M, Lupardus P, Balazs M, Swem LR. 2013. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14:93–103. https://doi.org/10.1016/j.chom.2013.06.004.
12. Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, Fouts A, Lupardus P, Wu TD, Li O, McBride J, Lawrence M, Xu M, Tan MW. 2016. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog 12:e1005702. https://doi.org/10.1371/journal.ppat.1005702.
13. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371: 37–43. https://doi.org/10.1038/371037a0.
14. Wiley DC, Skehel JJ. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56:365–394. https://doi.org/10.1146/annurev.bi.56.070187.002053.
15. Lim J, Deng R, Derby M, Larouche R, Horn P, Anderson M, Maia M, Carrier S, Pelletier I, Burgess T, Kulkarni P, Newton E, Tavel JA. 2016. Two phase 1, randomized, double-blind, placebo-controlled, single ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob Agents Chemother 60:5437–5444. https://doi.org/10 .1128/AAC.00607-16.
16. McBride J, Rosenberger C, Tavel J, Deng R, Derby M, Burgess T, Chai N, Park S, Xu M, Swem L. 2015. Clinical safety and efficacy of MHAA4549A, a novel monoclonal antibody for the treatment of severe influenza A: results of a randomized, double-blind, placebo-controlled clinical trial, abstr 2061. Abstr 2015 Keystone Symp Conf Viral Immun, Breckenridge, CO.
17. Monto AS, Ceglarek JP, Hayner NS. 1981. Liver function abnormalities in the course of a type A (H1N1) influenza outbreak: relation to Reye’s syndrome. Am J Epidemiol 114:750–759. https://doi.org/10.1093/oxfordjournals.aje.a113246.
18. Polakos NK, Cornejo JC, Murray DA, Wright KO, Treanor JJ, Crispe IN, Topham DJ, Pierce RH. 2006. Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol 168:1169–1178. https://doi.org/10.2353/ajpath.2006.050875.
19. Yingying C. 2011. Abnormal liver chemistry in patients with influenza A H1N1. Liver Int 31:902. https://doi.org/10.1111/j.1478-3231.2011.02519.x.
20. Deng R, Lee AP, Maia M, Lim JJ, Burgess T, Horn P, Derby MA, Newton E, Tavel JA, Hanley WD. 21 June 2017. Pharmacokinetics of MHAA4549A, an anti-influenza A monoclonal antibody, in healthy subjects challenged with influenza A virus in a phase IIa randomized trial. Clin Pharmacokinet https://doi.org/10.1007/s40262-017-0564-y.
21. Barroso L, Treanor J, Gubareva L, Hayden FG. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 10:901–910.
22. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240 –1246. https://doi.org/10.1001/jama.282.13.1240.
23. Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, Fredlund P, Swiderek KM. 2015. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211:1038–1044. https://doi.org/10.1093/infdis/jiu539.
24. Patel K, Smith PF, Dall G, Lovern M, Sloan S, Trevejo J, Hershberger E. 2017. Population pharmacokinetic and viral dynamic modeling of VIS410, a monoclonal antibody against influenza A virus in a human challenge model, abstr 3648. Abstr 2nd Annu Meet ASM Microbe, New Orleans, LA.
25. Fry AM, Zhong W, Gubareva LV. 2015. Advancing treatment options for influenza: challenges with the human influenza challenge. J Infect Dis 211:1033–1035. https://doi.org/10.1093/infdis/jiu543.
26. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenza-specific CD4 T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274–280. https://doi.org/10.1038/nm.2612.
27. Jegaskanda S, Luke C, Hickman HD, Sangster MY, Wieland-Alter WF, McBride JM, Yewdell JW, Wright PF, Treanor J, Rosenberger CM, Sub-barao K. 2016. The generation and protective ability of influenza-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection or experimental challenge. J Infect Dis 214: 945–952. https://doi.org/10.1093/infdis/jiw262.
28. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. 2015. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis 212:1191–1199. https://doi.org/10.1093/infdis/jiv195.
29. Deng R, Jin F, Prabhu S, Iyer S. 2012. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8:141–160. https://doi.org/10.1517/17425255.2012.643868.
30. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X. 2011. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29: 158–163. https://doi.org/10.1038/nbt.1742.
31. Sobel Leonard A, McClain MT, Smith GJ, Wentworth DE, Halpin RA, Lin X, Ransier A, Stockwell TB, Das SR, Gilbert AS, Lambkin-Williams R, Ginsburg GS, Woods CW, Koelle K. 2016. Deep sequencing of influenza A virus from a human challenge study reveals a selective bottleneck and only limited intrahost genetic diversification. J Virol 90:11247–11258. https://doi.org/10.1128/JVI.01657-16.
32. Dey S, Gupta S. 2013. Numerical methods. McGraw Hill Education (India) Private Limited, New Delhi, India.